Literature DB >> 8369525

The prognostic effect of histological tumor grade in node-negative breast cancer patients.

M Schumacher1, C Schmoor, W Sauerbrei, A Schauer, L Ummenhofer, W Gatzemeier, H Rauschecker.   

Abstract

The prognostic effect of histological tumor grade was evaluated in 1036 patients with early breast cancer (pT1 pN0 M0) entered into a trial comparing mastectomy and breast preserving treatment. All analyses were adjusted for the factors treatment, patients' age, and tumor size. Tumor grade was defined according to Bloom and Richardson based on the sum of scores assigned to each of three histological features: 1) degree of differentiation, 2) pleomorphism, and 3) mitotic index. The relative importance of these factors with regard to disease-free survival was evaluated. In univariate as well as in multivariate analyses the pleomorphism was the only factor showing a significant effect (univariate: p = 0.0024, multivariate: p = 0.015). It was investigated how the factors should be combined to define a histological grading score which yields the best possible classification of the patients with respect to prognosis. A new grading system was defined splitting the patients into three groups: 1) pleomorphism 1; 2) pleomorphism 2 or pleomorphism 3 and mitotic index 1; 3) pleomorphism 3 and mitotic index 2 or 3. This yields a good classification of the patients with respect to prognosis (p = 0.0004). The prognostic effect of this score was compared with the effects of the grading systems proposed in the literature. According to Bloom and Richardson and in the modified version by Schauer and Weiss, grading is based on the sum of scores of the various histological factors. Therefore, the strong effect of the pleomorphism was diluted in these grading definitions (Bloom and Richardson: p = 0.03, Schauer and Weiss: p = 0.028). The grading system proposed by Le Doussal et al. consists only of the scores of pleomorphism and mitotic index (p = 0.014). In summary, the factor pleomorphism showed a stronger effect on disease-free survival by itself than the grading systems proposed in the literature.

Entities:  

Mesh:

Year:  1993        PMID: 8369525     DOI: 10.1007/bf00689838

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

Review 1.  Tumor grade as a prognostic factor in primary breast cancer.

Authors:  G Contesso; G S Jotti; G Bonadonna
Journal:  Eur J Cancer Clin Oncol       Date:  1989-03

Review 2.  How to use prognostic factors in axillary node-negative breast cancer patients.

Authors:  W L McGuire; A K Tandon; D C Allred; G C Chamness; G M Clark
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

3.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.

Authors:  E G Mansour; R Gray; A H Shatila; C K Osborne; D C Tormey; K W Gilchrist; M R Cooper; G Falkson
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

4.  Adjuvant therapy of node-negative breast cancer.

Authors:  W L McGuire
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

5.  Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial.

Authors:  F Rank; P Dombernowsky; N C Jespersen; B V Pedersen; N Keiding
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

6.  Nuclear characteristics as indicators of prognosis in node negative breast cancer patients.

Authors:  V le Doussal; M Tubiana-Hulin; K Hacene; S Friedman; M Brunet
Journal:  Breast Cancer Res Treat       Date:  1989-11       Impact factor: 4.872

7.  Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas.

Authors:  V Le Doussal; M Tubiana-Hulin; S Friedman; K Hacene; F Spyratos; M Brunet
Journal:  Cancer       Date:  1989-11-01       Impact factor: 6.860

8.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis.

Authors:  B W Davis; R D Gelber; A Goldhirsch; W H Hartmann; G W Locher; R Reed; R Golouh; J Säve-Söderbergh; L Holloway; I Russell
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

9.  Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors.

Authors:  R Sauer; A Schauer; H F Rauschecker; M Schumacher; W Gatzemeier; C Schmoor; J Dunst; M H Seegenschmiedt; D Marx
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 10.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

View more
  10 in total

1.  Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.

Authors:  Angélica Morales; Sumiko Morimoto; Felipe Vilchis; Natsuko Taniyama; Claudia J Bautista; Carlos Robles; Enrique Bargalló
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

2.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

3.  Interleukin-1 polymorphisms are associated with the inflammatory response in human muscle to acute resistance exercise.

Authors:  Richard A Dennis; Todd A Trappe; Pippa Simpson; Chad Carroll; B Emma Huang; Radhakrishnan Nagarajan; Edward Bearden; Cathy Gurley; Gordon W Duff; William J Evans; Kenneth Kornman; Charlotte A Peterson
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

4.  Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer.

Authors:  I Schönborn; W Zschiesche; C Minguillon; E Spitzer; M Möhner; K Ebeling; R Grosse
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Therapy of small breast cancer--four-year results of a prospective non-randomized study. German Breast Cancer Study Group (GBSG).

Authors: 
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

6.  Morphometric grading of breast cancer: thresholds for tubular differentiation.

Authors:  P Kronqvist; T Kuopio; Y Collan
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

7.  Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG).

Authors:  W Sauerbrei; P Royston; H Bojar; C Schmoor; M Schumacher
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics.

Authors:  Hadar Goldvaser; Shulamith Rizel; Daniel Hendler; Victoria Neiman; Daniel Shepshelovich; Tzippy Shochat; Aaron Sulkes; Baruch Brenner; Rinat Yerushalmi
Journal:  Int J Endocrinol       Date:  2016-08-28       Impact factor: 3.257

9.  Amplification of Genomic DNA for Decoy Receptor 3 Predicts Post-Resection Disease Recurrence in Breast Cancer Patients.

Authors:  Chizuko Kanbayashi; Yu Koyama; Hiroshi Ichikawa; Eiko Sakata; Miki Hasegawa; Chie Toshikawa; Naoko Manba; Mayuko Ikarashi; Takashi Kobayashi; Masahiro Minagawa; Shin-Ichi Kosugi; Toshifumi Wakai
Journal:  World J Oncol       Date:  2014-03-11

10.  Analysis of the potent prognostic factors in luminal-type breast cancer.

Authors:  Han-Sung Kim; Inseok Park; Hyun Jin Cho; Geumhee Gwak; Keunho Yang; Byung Noe Bae; Ki Whan Kim; Sehwan Han; Hong-Joo Kim; Young-Duck Kim
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.